Program
bilastine
Also written as “Bilastine”, “Bilastine oral dispersible tablets” and “Bilaxten oral dispersible tablets”.
Its studies are mostly in Rhinitis, Allergic, Seasonal · Conjunctivitis, Allergic · Urticaria · Rhinitis, Allergic · Asthma, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Faes Farma | 140 open or running | phase 3since Jan 9, 2007 | Jan 8, 2007 | none ahead |
| Menarini Group | 30 open or running | phase 4since Oct 13, 2015 | Oct 13, 2015 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Jun 20, 2025 | Jun 20, 2025 | none ahead |
| Yuhan | 10 open or running | phase 3since Jul 20, 2011 | Jul 20, 2011 | none ahead |
Also a collaborator on its studies: ORA, dynamic-science-s-l, allied-research-international and Merck.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Jan 8, 2007.
- Dec 12, 2007Phase 1 study in HealthyFaes Farma · NCT00572611 · 6 enrolled · United Kingdom
- Dec 14, 20072 phase 2 studies in Rhinitis, Allergic, SeasonalFaes Farma · NCT00574379, NCT00574210
- Mar 4, 2010Phase 2 study in Chronic UrticariaFaes Farma · NCT01081574 · 36 enrolled · Australia, Germany, Sweden
- Apr 21, 2010Phase 3 study in Rhinitis, Allergic, SeasonalFaes Farma · NCT01108783 · 720 enrolled
- May 13, 2010Phase 1 study in HealthyFaes Farma · NCT01124123 · 12 enrolled · Spain
- May 19, 2010Phase 3 study in Rhinitis, Allergic, PerennialFaes Farma · NCT01127620 · 650 enrolled
- Jul 20, 2011Yuhan's first study: phase 3 study in Rhinitis, Allergic, SeasonalNew to YuhanYuhan · NCT01400828 · 239 enrolled · Korea, Republic of
- Oct 13, 2015Menarini Group's first study: phase 4 study in Rhinitis, AllergicNew to Menarini GroupMenarini Group · NCT02576041 · 19 enrolled · Italy
- Apr 28, 2016Phase 4 study in AsthmaMenarini Group · NCT02761252 · 454 enrolled · Croatia, Czechia, Germany and more
- Jul 20, 2017Phase 2 study in Conjunctivitis, AllergicFaes Farma · NCT03231969 · 121 enrolled · United States
- Mar 21, 2018Phase 3 study in Conjunctivitis, AllergicFaes Farma · NCT03479307 · 228 enrolled · United States
- Aug 3, 2018Phase 1 study in PharmacokineticsMenarini Group · NCT03633760 · 24 enrolled · China
- Mar 1, 2021Phase 3 study in Conjunctivitis, AllergicFaes Farma · NCT04810390 · 59 enrolled · Spain
- Jun 20, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in UrticariaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07042828 · 42 enrolled · India
TargetBeta
“Histamine H1 receptor inverse agonist”ChEMBL 37, by rule
Other programs on HRH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| desloratadinerule | Organon | phase 4 | 40 |
| fexofenadinerule | Sanofi | phase 4 | 38 |
| Diphenhydraminerule | Johnson & Johnson | phase 4 | 16 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07042828Urticaria · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Jun 16, 2025 | 42 |
| NCT04810390Conjunctivitis, Allergic · Spain | 3 | Completed | Faes Farma | Nov 30, 2022 | 59 |
| NCT03633760Pharmacokinetics · China | 1 | UNKNOWN | Menarini Group | Apr 30, 2019 | 24 |
| NCT03479307Conjunctivitis, Allergic · United States | 3 | Completed | Faes Farma | Aug 9, 2018 | 228 |
| NCT03231969Conjunctivitis, Allergic · United States | 2 | Completed | Faes Farma | Oct 11, 2017 | 121 |
| NCT02761252Asthma · Croatia, Czechia, Germany and more | 4 | Completed | Menarini Group | Nov 24, 2016 | 454 |
| NCT02576041Rhinitis, Allergic · Italy | 4 | Completed | Menarini Group | Dec 2015 | 19 |
| NCT01400828Rhinitis, Allergic, Seasonal · Korea, Republic of | 3 | Completed | Yuhan | Jun 2013 | 239 |
| NCT01127620Rhinitis, Allergic, Perennial | 3 | Completed | Faes Farma | Mar 2006 | 650 |
| NCT01124123Healthy · Spain | 1 | Completed | Faes Farma | Jun 2010 | 12 |
| NCT01108783Rhinitis, Allergic, Seasonal | 3 | Completed | Faes Farma | Aug 2003 | 720 |
| NCT01081574Chronic Urticaria · Australia, Germany, Sweden | 2 | Completed | Faes Farma | Jun 2012 | 36 |
| NCT00574379Rhinitis, Allergic, Seasonal · United States | 2 | Completed | Faes Farma | Mar 2008 | 805 |
| NCT00574210Rhinitis, Allergic, Seasonal · Canada | 2 | Completed | Faes Farma | Feb 2008 | 502 |
| NCT00572611Healthy · United Kingdom | 1 | Completed | Faes Farma | Dec 2007 | 6 |
| NCT00504933Rhinitis, Allergic, Seasonal | 3 | Completed | Faes Farma | Nov 2005 | 683 |
| NCT00421109Urticaria · Argentina, Belgium, France and more | 3 | Completed | Faes Farma | Jul 2007 | 522 |
| NCT00420082Rhinitis, Allergic, Seasonal · Austria | 2 | Completed | Faes Farma | 75 | |
| NCT00419783Rhinitis, Allergic · United States | 1 | Completed | Faes Farma | Dec 2006 | 30 |
How it is read
Names in the registry
- “Bilastine”, 13 entries
- “bilastine”, 2 entries
- “Bilastine oral dispersible tablets”, 1 entry
- “Bilaxten oral dispersible tablets”, 1 entry
- “Bilastine 0.2%”, 1 entry
Conditions, from the studies’ own filings
- Rhinitis, Allergic, Seasonal, 6 studies
- Conjunctivitis, Allergic, 3 studies
- Urticaria, 2 studies
- Rhinitis, Allergic, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.